2024 (1 POST)
Davies S, Boller E, Chase J, Beaubrun A, Miller C, Jensen I . 2024. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses. J Med Econ 27(1):430–441; doi: 10.1080/13696998.2024.2313391 .
View Abstract
Publication: Manuscripts
2023 (7 POSTS)
Gutierrez M, Wild S, Compton A, Paine E, Jensen I , Shah A. Cost consequences of using clevidipine in neurological emergencies from the perspective of a US hospital. Abstract EE579 . ISPOR EU 2023.
View Abstract
Publication: Abstracts and Presentations
Gutierrez M, Wild S, Compton A, Paine E, Jensen I , Shah A. Cost consequences of using clevidipine in cardiac surgery from the perspective of a US hospital. Abstract EE734 . ISPOR EU 2023.
View Abstract
Publication: Abstracts and Presentations
Gutierrez M, Wild S, Compton A, Paine E, Jensen I , Shah A. Cost consequences of using clevidipine in acute hypertension from the perspective of a US hospital. Abstract EE125 . ISPOR EU 2023.
View Abstract
Publication: Abstracts and Presentations
Bean K, Miller B, Jensen I , Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547 . ISPOR EU 2023.
View Abstract
Publication: Abstracts and Presentations
Miller B, Russel-Szymczyk M, Jensen I , Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. Abstract EE658 . ISPOR EU 2023.
View Abstract
Publication: Abstracts and Presentations
Davies S, Boller E, Beaubrun A, Miller C, Jensen I . A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV Plus for the diagnosis of viral respiratory infections from a US health plan perspective. Abstract ID309 . AMP 2023 Annual Meeting & Expo.
View Abstract
Publication: Abstracts and Presentations
Jensen I , Srivastava K, Minshall M, Kemp R. Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome. Abstract EE539 . ISPOR 2023.
View Abstract
Publication: Abstracts and Presentations
2022 (3 POSTS)
Jensen I , Cyr P . 2022. Early health economic models in gene and cell therapy to inform clinical trial design and optimize commercialization efforts. White Paper. PharmaLive .
Publication: White paper
Yao W, Jensen I , Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi: 10.5863/1551-6776-27.8.695 .
View Abstract
Publication: Manuscripts
Pang F, Dean R, Jensen I , Tehard B, Roze S, Olaye A, et al. The cost-effectiveness of atidarsagene autotemcel for the treatment of metachromatic leukodystrophy (MLD) in France. Abstract EE24 . ISPOR 2022.
View Abstract
Publication: Abstracts and Presentations
2021 (1 POST)
Alexander W, Jensen I , Hathway J, Srivastava K, Cyr P, Batt K. Economic IMPACT of utilizing eptacog beta for the on-demand treatment of bleeding events among hemophilia patients with inhibitors. Abstract PBI11 . ISPOR 2021 Annual International Meeting.
View Abstract
Publication: Abstracts and Presentations
2020 (1 POST)
Hathway J, Miller-Wilson L, Jensen I , Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123 .
View Abstract
Publication: Manuscripts
2014 (1 POST)
Jensen IS , Halbert RJ, Thompson SF, Hennessy D, Pacconi S, McSweeney PA. Increased use of plerixafor in patients with multiple myeloma and non-Hodgkin lymphoma in the United States: A budgetary impact analysis. Abstract C14 . Academy of Managed Care Pharmacy 26th Annual Meeting & Expo 2014.